On this page

Triamcinolone Acetonide

Prescription Veterinary ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Triamcinolone Acetonide
Generic name
Triamcinolone Acetonide
Dosage form
Paste
Route
Dental
Marketing category
ANDA · ANDA
Labeler
Preferred Pharmaceuticals Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
8
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Triamcinolone Acetonide 1 mg/g 1014314 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Paste
Route of administration
Dental
Presentations
18

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
205592
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 12, 2017
Sponsor
COSETTE PHARMS NC
Products on application
1
Submissions recorded
1
Products approved under application 205592.
Product Trade name Form Strength Ingredient Status TE Flags
205592-001 TRIAMCINOLONE ACETONIDE PASTE TRIAMCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 205592.
Type No. Action Status Date Review
Original application 1 Approved January 12, 2017 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250915). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250915 HUMAN PRESCRIPTION DRUG · 20250411 HUMAN PRESCRIPTION DRUG · 20241120 HUMAN PRESCRIPTION DRUG · 20230215

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Triamcinolone Acetonide Dental Paste USP, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Press a small dab (about 1/4 inch) to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops. The preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. If significant repair or regeneration has not occurred in seven days, further investigation is advisable.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Triamcinolone Acetonide Dental Paste USP, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa. Also, see PRECAUTIONS for potential effects of systemic absorption. To report SUSPECTED ADVERSE REACTINS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Triamcinolone Acetonide Dental Paste USP, 0.1%, contains the corticosteroid triamcinolone acetonide in an adhesive vehicle suitable for application to oral tissues. Triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The structural formula of triamcinolone acetonide is as follows: C 24 H 31 FO 6 MW 434.50 Each gram of triamcinolone acetonide dental paste contains 1 mg triamcinolone acetonide in an emollient dental paste containing carboxymethylcellulose sodium, gelatin, and pectin in a plasticized hydrocarbon gel (a polyethylene and mineral oil gel base). Chemical Structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Triamcinolone Acetonide Dental Paste USP, 0.1% is supplied as light beige odorless paste with fine gritty texture, having no lumps filled in aluminum or laminated tubes containing 5 g of dental paste in laminated tubes (NDC 70752-140-16) and 5 g of dental paste in aluminum tubes (NDC 70752-140-17). Storage Keep tightly closed. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Adverse event reports

Source: openFDA FAERS
31,697
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
72162-2318-2 72162-2318 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2318-2) / 5 g in 1 TUBE May 20, 2024
0713-0655-40 0713-0655 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0655-40) / 5 g in 1 TUBE January 13, 2017
68788-7814-5 68788-7814 Preferred Pharmaceuticals Inc 1 TUBE in 1 CARTON (68788-7814-5) / 5 g in 1 TUBE November 3, 2020
68788-8841-5 68788-8841 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8841-5) / 5 g in 1 TUBE March 20, 2025
68788-8386-5 68788-8386 Preferred Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68788-8386-5) / 5 g in 1 TUBE March 1, 2023
70752-140-16 70752-140 QUAGEN PHARMACEUTICALS LLC 1 TUBE in 1 CARTON (70752-140-16) / 5 g in 1 TUBE January 15, 2023
70752-140-17 70752-140 QUAGEN PHARMACEUTICALS LLC 1 TUBE in 1 CARTON (70752-140-17) / 5 g in 1 TUBE January 15, 2023
64980-320-05 64980-320 Rising Pharma Holdings, Inc. 48 CARTON in 1 BOX (64980-320-05) / 1 TUBE in 1 CARTON / 5 g in 1 TUBE July 7, 2010
51672-1267-5 51672-1267 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1267-5) / 5 g in 1 TUBE October 1, 1986
51672-1267-8 51672-1267 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1267-8) / 7.5 g in 1 TUBE October 1, 1986
72162-2318 72162-2318 Bryant Ranch Prepack — January 15, 2023
0713-0655 0713-0655 Cosette Pharmaceuticals, Inc. — January 13, 2017
68788-7814 68788-7814 Preferred Pharmaceuticals Inc — November 3, 2020
68788-8841 68788-8841 Preferred Pharmaceuticals Inc. — March 20, 2025
68788-8386 68788-8386 Preferred Pharmaceuticals, Inc. — March 1, 2023
70752-140 70752-140 QUAGEN PHARMACEUTICALS LLC — January 15, 2023
64980-320 64980-320 Rising Pharma Holdings, Inc. — July 7, 2010
51672-1267 51672-1267 Sun Pharmaceutical Industries, Inc. — October 1, 1986

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.